Skip to main content
. 2020 Dec 4;48(22):12778–12791. doi: 10.1093/nar/gkaa1145

Figure 1.

Figure 1.

RAD521–209 forms nuclear foci in response cisplatin treatment in U2OS cells. (A) The scheme of RAD52WT and RAD521–209 constructs containing HA-tag at the N-terminus. RAD52 NTD domain contains DNA binding region and a region for oligomerization (blue; 85–159 residues). RAD52 CTD contains RPA binding region (yellow; 221–280 residues), RAD51 binding region (brown; 291–330 residues) and nuclear localization signal (NLS) (green; 405–414 residues). 405–418 residues containing NLS was added to RAD521–209 at the C-terminus. (B) Representative images of U2OS RAD52 knock-out (KO) cells stably expressing RAD52WT or RAD521–209 or no exogenous RAD52 stained with DAPI (blue), fluorescent anti-bodies for RAD52 (green) and γ-H2AX (red) 6 h after cisplatin (5 μM) treatment.